The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setback For Merck’s HIV Program, Decision Day For Daré
Here's a roundup of top developments in the biotech space over the last 24 hours:
Mizuho Maintains Buy on Cytokinetics, Raises Price Target to $54
Mizuho analyst Salim Syed maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $45 to $54.
Cytokinetics Q3 EPS $(0.95) Misses $(0.76) Estimate, Sales $5.40M Miss $6.42M Estimate
Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.76) by 25 percent. This is a 1800 percent decrease over losses of $(0.05) per share from the
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell
• R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.
Cytokinetics Announces Preclinical Data Relating To CK-3828136 Presented At 2021 Medicinal Chemistry Gordon Research Conference
Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that preclinical data relating to the discovery and optimization of CK-3828136 (CK-136) were presented at the 2021 Medicinal Chemistry Gordon Research Conference
Where Cytokinetics Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Cytokinetics (NASDAQ:CYTK) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Morgan Stanley Maintains Overweight on Cytokinetics, Raises Price Target to $45
Morgan Stanley analyst Jeffrey Hung maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $38 to $45.
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
Expert Ratings For Cytokinetics
Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter:
